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Abstract
Anemia is an important public health problem that negatively affects health of individuals and 
economic potential of populations. An accurate case definition is critical for understanding burden 
and epidemiology of anemia, for planning public health interventions, and for clinical 
investigation and treatment of patients. The current threshold hemoglobin concentrations for 
diagnosis of anemia were proposed in 1968 and based on studies predominantly of Caucasian 
adult populations in Europe and North America. The World Health Organization is undertaking a 
project to review global guidelines for anemia. We describe the process of obtaining input from 
technical experts, researchers, blood bank experts, policy makers, and program implementers to 
identify key information or knowledge gaps for anemia diagnosis. From this scoping exercise, six 
priority areas were identified on diverse topics related to the use and interpretation of hemoglobin 
concentrations to diagnose anemia in individuals and populations. A call for authors was 
conducted to produce background, review, and research papers across priority topics. This paper 
summarizes the first technical meeting, which included commissioned papers as well as case 
studies, describes key data gaps identified, and describes the next steps in the guideline 
development process to assess available evidence and define knowledge gaps to improve anemia 
characterization.
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Introduction
Anemia is a condition in which the number of red blood cells or their oxygen-carrying 
capacity is insufficient to meet physiologic needs. Definitions of hemoglobin thresholds 
used to diagnose anemia vary by age, sex, elevation above sea level, smoking, and pregnancy 
status.1 Accurate characterization of anemia is critical to understanding the burden and 
distribution of this condition, for planning public health interventions, and for 
comprehensive and integrated health services (promotive, protective, preventive, curative, 
rehabilitative, and palliative) throughout the life course, prioritizing primary care and 
essential public health functions. The threshold hemoglobin concentration for diagnosis of 
anemia, used in the clinical investigation and management of patients, is presently defined 
below the putative 95% reference range in normal individuals adjusted for age, sex, and 
pregnancy status, with corrections for elevation of place of residence and smoking practices.
2
 Definitions of anemia have impacts both on public health programs and on clinical 
decision making.
Hemoglobin thresholds to define anemia were first proposed by the World Health 
Organization (WHO) in 1959. Current thresholds recommended by WHO for men, women, 
young children, and during pregnancy were proposed in 1968 after technical meetings with 
clinical and public health experts working with the evidence available at the time;3 data 
consisted of studies predominantly of Caucasian adult populations in Europe and North 
America.4–7 Data from other countries, ethnic groups, and ages (i.e., infants, young children, 
adolescents, and the elderly) were not available to the panel.8
There are concerns that current thresholds may not appropriately define anemia in all 
populations to which they have been applied; for example, in individuals of African or Asian 
populations, in young children and older persons, and in different stages of pregnancy. 
Hemoglobin thresholds that appropriately indicate a detrimental health outcome or 
underlying symptoms remain undefined. There are also uncertainties concerning optimal 
testing methods for hemoglobin concentration.
The prevention and control of anemia is one of the WHO 2025 global nutrition targets.9 
Improved definitions of anemia would allow a more accurate assessment of the 
determinants, their burden, and hence the impact of this condition on individuals and in 
populations.2,10 From a public health point of view, governments, nongovernmental 
organizations, and donors will be able to better target nutrition-specific and -sensitive 
interventions in primary health care, monitor the effectiveness of programs, and make 
informed decisions regarding allocation of resources to address the determinants of health, 
leaving no one behind. From a clinical perspective, measurement of hemoglobin is one of 
the most commonly performed laboratory tests in the primary health care, hospital, and 
critical care setting.11,12 Updated definitions of anemia would help health professionals 
manage, investigate, and treat their patients.13,14
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WHO project to review hemoglobin thresholds to diagnose anemia
The WHO is undertaking a project to review its global guidelines for hemoglobin thresholds 
used to define anemia at the individual and population level and determine the impact of 
health interventions.
As the first step, more than 4000 technical experts, researchers, blood bank experts, policy 
makers, and program implementers were asked to identify priority questions to understand 
the key information and knowledge that would enable a revised definition of hemoglobin 
thresholds, in the form of a prioritized list of scoping questions (http://www.who.int/
nutrition/events/2016_online_consultation_haemoglobin_anemia/en/). Over 500 questions 
from more than 150 respondents were received and consolidated into 58 questions across six 
categories that were ranked by responders as the most relevant aspects on anemia diagnosis. 
The six categories were: physiology of anemia, hemoglobin cutoffs for different population 
groups, definition of anemia across clinical and environmental contexts, approaches to 
develop anemia cutoffs, laboratory and diagnostic considerations, and the use of WHO 
hemoglobin cutoffs guidelines. Based on the questions and research needs that scored 
highest by stakeholders, top ranked questions were identified.15
A call for authors was launched to invite clinicians, hematologists, physicians, nutritionists, 
epidemiologists, health economists, basic scientists, and researchers interested in preparing 
review papers on the six categories identified through the prioritization exercise and other 
diverse topics related to the use and interpretation of hemoglobin concentrations to diagnose 
anemia in individuals and in populations (http://www.who.int/nutrition/
callforauthors_anemia_status/en/). The topics requested were: (1) pathophysiology of 
anemia; (2) effects of genetic variants on hemoglobin concentration; (3) variation in 
hemoglobin thresholds for anemia across the life cycle; (4) hypoxia, altitude, and other 
psychobiological aspects affecting hemoglobin concentrations; (5) effect of maternal 
hemoglobin levels on mother and child health; (6) effect of hemoglobin concentrations on 
cognitive and physical development in children; (7) defining anemia as a public health 
problem and classifying severity; (8) hemoglobin for monitoring clinical and nutrition-
specific/nutrition-sensitive interventions; (9) optimal methods for hemoglobin measurement 
in clinical laboratories and field studies; (10) ethics, human rights, and determinants of 
equity in access to anemia diagnosis; (11) modeling of cutoff points for diagnosing anemia; 
and (12) country experiences and case studies (Table 1). Thirty-three paper proposals 
covering 11 of these 12 topics were received, and 17 papers were commissioned after 
editorial review.
WHO technical meeting
The Evidence and Programme Guidance Unit, Department of Nutrition for Health and 
Development of the World Health Organization convened the technical meeting: “Use and 
interpretation of hemoglobin concentrations for assessing anemia status in individuals and 
populations,” held in Geneva, Switzerland in November 29–30 and December 1, 2017 
(http://www.who.int/nutrition/events/2017-meeting-haemoglobin-concentrations-
anemia-29novto1dec/en/).
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The objectives of the meeting were to review:
1. The definition of anemia as a public health problem and classification of severity.
2. Variation in hemoglobin thresholds for anemia across the life cycle and other 
psychobiological aspects affecting hemoglobin concentrations.
3. The effect of hemoglobin levels on maternal and child health, including cognitive 
and physical development in children.
4. The diagnostic value of hemoglobin concentration for monitoring clinical and 
nutrition-specific/nutrition-sensitive interventions.
5. Methods for hemoglobin measurement in clinical laboratories and field studies.
6. Ethics, human rights, and determinants of equity in access to anemia diagnosis.
7. Country-level experiences and lessons learned about hemoglobin determinations 
and anemia diagnosis.
8. Research priorities to fill data gaps related to nutrition interventions to reduce 
anemia and unintended adverse effects.
The technical meeting was based on, but not limited to, the background papers and case 
studies that were commissioned through the public call for papers. It included the 
presentation of the commissioned papers and other topics of interest, plenary discussions, 
and a session for developing a scoping document as a base for developing PICO questions 
(Populations, Interventions, Comparisons, Outcomes) that will help with the development of 
WHO guidelines in the near future.
One of the outcomes of the WHO project on reviewing hemoglobin thresholds is the 
publication of a special issue in a peer-reviewed journal, containing the commissioned 
papers and results from this technical meeting. This introductory paper to the special issue 
provides the background and rationale of the technical consultation, synopsizes the 
presentations, summarizes the main considerations proposed at the meeting, and identifies 
the research needs and the way forward for the assessment of anemia.
The meeting opened with presentations high-lighting the importance of anemia as part of the 
WHO 2025 global nutrition targets,9 indicating that anemia is at the heart of the health and 
development agenda and that there are many aspects that are unclear or unknown about 
definitions, prevalence, significance, or the proportion of anemia that is responsive to 
nutritional or other health measures. The objectives of the WHO anemia project and the 
objectives of the meeting were presented, and participants were invited to challenge the 
current definitions of anemia and the review of thresholds from a clinical and from a public 
health point of view, considering implications and consequences of each approach. 
Participants were reminded that ultimately the aim of the project is to obtain accurate and 
justifiable definitions of anemia and to define guidelines for its assessment.
There was an introductory group of presentations to set the basis for discussions: definition 
of anemia and causes and consequences;10,16 WHO anemia prevalence estimates;17–19 
genetic variations associated with hemoglobin across populations; and the biology of 
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autoimmune hemolytic anemia. The first plenary session focused on the high prevalence of 
anemia worldwide and showed that anemia tends to be most prevalent in areas of the world 
where nutritional, infectious, and genetic causes of anemia are common. The need to 
standardize the definition and recognizing the need to include factors affecting the etiology 
of anemia when establishing hemoglobin thresholds were discussed. Addressing ethnicity in 
the definition of anemia was proposed, as well as considerations about its role in influencing 
thresholds. It was observed that evidence for thresholds for infants and older persons was 
inadequate, that differences in thresholds between the sexes should be considered for all age 
groups, and that how genetic variation should be accounted for is an unresolved issue that 
clearly affects some settings more than others. It was emphasized that different settings may 
require distinct thresholds for anemia given the genetic variations associated with anemia.
There was a group of related presentations that addressed the statistical and functional 
changes in definitions of anemia over the life course. The paucity of evidence for different 
thresholds over the life course in different geographic settings was described. The results 
from a systematic review on associations and effects of increased hemoglobin in preschool 
children on growth, development, and chronic disease; the role of etiology of anemia and 
timing of measurement on maternal hemoglobin concentrations and maternal and child 
health; and the results from another systematic review on the effects of maternal hemoglobin 
concentrations on maternal and child health in different WHO regions of the world were 
presented. This group of presentations highlighted concerns related to anemia cutoffs by age, 
gender, and ethnicity. From the data presented, there was inadequate evidence to tie 
hemoglobin concentrations to functional outcomes. However, maternal anemia was 
correlated to negative birth outcomes, but correlations were less clear for maternal outcomes.
The effects of physiologic hypoxia on hemoglobin thresholds were considered next. The 
need for adjustments on hemoglobin cutoffs for elevation above sea level and smoking was 
addressed through a systematic review, an analysis of pooled multicountry data, and 
description of a country experience. In a systematic review of reference values for 
hemoglobin in populations living at varying altitude, the presenters found evidence that 
humans may adapt to hypoxia from altitude differently based on ethnicity,20,21 mediated via 
a polymorphism in genes involved in sensing hypoxia. Although there are limited data, at the 
same altitude Tibetan children have lower hemoglobin concentrations compared to Han 
Chinese, while Andean children have higher hemoglobin concentrations compared to Han; 
these findings may be explained by genetic differences in populations.22 The other analysis 
used amalgamated data from 14 population-based nutrition surveys among 13 countries 
from the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia 
(BRINDA) project,23,24 and studies containing data on altitude, smoking, and hemoglobin 
(Bolivia and Guatemala) to examine effects of elevation above sea level and smoking on 
hemoglobin concentration. The experience from Bolivia in children under 5 years of age 
included a comparative analysis among three regions of different altitudes showing a high 
prevalence of anemia, and that the factors associated with anemia in children varied by 
elevation above sea level. Smoking, electronic cigarettes, indoor cooking stoves, and effects 
on hemoglobin were discussed. Collectively, these studies indicated that current hemoglobin 
adjustments for altitude may be too large, especially at higher altitudes, and may require 
reconsideration.
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The next block of presentations was related to the definitions of severity of anemia at the 
clinical level, and the definition of mild, moderate, and severe burdens of anemia at the 
public health level. It was clear that an evidence-based definition of hemoglobin thresholds 
is needed for clinical thresholds. The causes of anemia, especially the contribution of iron 
deficiency to anemia severity, were constantly addressed during discussions. The role of 
hemoglobinopathies, infections, and inflammation—of any origin and degree—needs to be 
taken into consideration when defining hemoglobin cutoff points. The evidence for 
transfusion thresholds was also addressed, highlighting that the need and point for initiating 
transfusion deserves careful consideration and clear criteria for donors and transfused 
individuals.25–27
Laboratory methodologies for assessment of hemoglobin concentrations were discussed. 
After three presentations, participants discussed concerns about reproducibility of methods 
and feasibility in field studies. Concern was expressed about comparability and performance 
between different platforms, especially the HemoCue® system compared with others and 
between different editions of the same instrument/system. A key emerging problem observed 
in field epidemiologic studies is the divergence in venous and capillary hemoglobin 
measurements; these discrepancies raise the possibility that current estimates of the global 
prevalence of anemia are overestimated as most population-based estimates used capillary 
measures of hemoglobin. Concern was expressed about the HemoCue system having 
proprietary quality controls, the frequency of routine use of these controls in field practice, 
and the need to ensure calibration materials for all instruments are commutable to 
international reference materials/standards. The practicality of implementing various assays 
in field studies, techniques for laboratory quality control, strategies for field workers, and 
phlebotomist training were also discussed. The need for guidance on controlling for these 
various critical preanalytic aspects was emphasized.
Finally, the meeting addressed other factors affecting anemia prevalence. There were 
presentations on the complex interaction between malaria, iron metabolism, and anemia; 
associations between water sanitation and hygiene conditions and anemia prevalence; and 
the role of nutrition-related interventions for preventing and controlling anemia through the 
life cycle. Ethical and human rights considerations related to the accuracy and interpretation 
of hemoglobin concentrations for anemia diagnosis were also explored.
Closing remarks and research needs
The final session of the meeting was devoted to in-depth discussions and clarifications, and 
to launching an approach to defining PICO questions, which are critical to scoping future 
WHO guidelines and identifying knowledge gaps, and hence research priorities critical to 
developing the evidence needed to support the guidelines. Other aspects, such as anemia 
severity, public health significance, and laboratory methods, were also considered.
The meeting highlighted key uncertainties in incumbent thresholds and approaches to 
defining anemia. Importantly, there is negligible evidence to support current hemoglobin 
thresholds in infancy, childhood, pregnancy, and the elderly. Likewise, it is unclear whether 
the same thresholds should be used across different ethnicities, or how genetic propensity to 
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hemoglobin variants should be accounted for in individual clinical diagnosis and population 
estimates of anemia prevalence. The hemoglobin concentrations associated with acute 
clinical adverse events (i.e., symptomatic anemia or exacerbation of medical conditions in 
individuals with chronic diseases, such as ischemic heart disease) are uncertain. The 
hemoglobin thresholds below which adverse functional outcomes are observed in children 
(e.g., impaired future development) and pregnancy (e.g., diminished birth weight) are 
likewise uncertain. Uncertainty in anemia definitions is reflected by heterogeneity in 
thresholds recommended by professional organizations.
Several crucial questions must be considered to improve current hemoglobin thresholds to 
define anemia. Diagnostic thresholds can be defined through a variety of approaches. First, 
anemia could be defined by hemoglobin levels below the reference range, that is, below a 
statistical centile (e.g., the 2.5th centile of hemoglobin in a healthy population). 
Alternatively, anemia may be considered to reflect thresholds below which clinical 
symptoms (e.g., fatigue and lethargy) or exacerbation of underlying clinical conditions (e.g., 
congestive cardiac failure or ischemic heart disease) appear. Anemia could also be defined as 
hemoglobin levels below which individuals are at risk of functional adverse consequences—
for example, in pregnant women, reduced birth weight, or prematurity; and in infants, 
reduced cognitive development. Finally, it may be critical to detect anemia at a hemoglobin 
threshold where individuals have a risk of an underlying clinical or medical condition that 
necessitates further investigation—for example, a genetic condition (e.g., carriage of 
thalassemia), a nutritional deficiency, inflammation, or chronic bleeding.
It will be important to consider groups of individuals for whom thresholds may need to vary
—for example, thresholds currently differ between under-5 children, school-age children, 
and adults; between adult males and females; and between nonpregnant and pregnant adult 
females.8 It is important to consider whether these groups are appropriate or whether more 
narrowly defined group-specific thresholds are required—for example, among younger 
infants, across different trimesters of pregnancy, and in the elderly. Likewise, it will be 
important to consider whether the same thresholds are appropriate in all populations and 
across different countries and in people of different ethnicities, or whether different 
thresholds should be developed.
There remains considerable uncertainty regarding preanalytic variables associated with 
hemoglobin measurement, especially the differences in hemoglobin concentration between 
venous and capillary blood collection, and whether these can be sufficiently overcome for 
routine use of capillary measurement in the field. There is also concern regarding the 
validity of hemoglobin measurements using point-of-care analyzers compared with 
automated hematology analyzers. In low- and middle-income countries, other techniques for 
hemoglobin estimation are still used, for example, filter paper methods, manual 
cyanmethemoglobin measurement using spectrophotometry, and other measures. 
Noninvasive techniques for assessment of hemoglobin measurement are entering clinical 
practice in some settings and may become more established in the medium term. However, 
the validity of these methods needs to be determined.
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At the population level, it will be important to consider how the public health relevance of 
anemia prevalence should be determined. This is critical to determine settings in which 
nutrition-specific (e.g., iron supplementation) or-sensitive (e.g., malaria control) 
interventions may be beneficial. Currently, the population-level problem of anemia is 
predominantly derived from estimates in under-5 children and women; are these the optimal 
and only groups that should be considered in routine surveys and global estimates?
Guideline development
WHO will convene a formal Guideline Development Process to assess the available 
evidence and define critical evidence needs. Some aspects may be able to be addressed using 
available evidence—for example, analyses of effects of altitude on thresholds. However, for 
other issues, new data and evidence will be needed.
Based on what was presented at the Consultation, there are minimal data to support 
hemoglobin thresholds to define anemia. There is a paucity of evidence for thresholds across 
the life cycle and in individuals of different ethnicities and from different countries. A 
multicenter hemoglobin reference study (akin to similar international studies such as the 
WHO multicenter growth reference study and the WHO fetal growth study) could define the 
2.5th centile across healthy individuals of different age groups and geographic settings. Such 
a study would confirm whether thresholds are consistent across different populations and 
provide an opportunity to confirm the effects of genetic variants (e.g., thalassemia carriage) 
on thresholds. The need and possible design for such a study is presently being defined.
While anemia is associated with adverse outcomes in pregnancy, evidence linking anemia to 
adverse developmental outcomes in infants is less clear. In both cases, evidence for specific 
thresholds that link to functional outcomes is absent. Individual patient data meta-analysis of 
cohort studies, or analysis of prospective cohort data, could define these associations and 
identify hemoglobin thresholds correlated to functional detriments.
Detailed studies to compare hemoglobin levels assessed across different preanalytic 
specimens and using different analytic platforms are necessary to enable interpretation of 
data from surveys, and to confirm validity of studies and clinical testing using these different 
approaches. Additionally, considerations of including methodological recommendations 
about sampling, source of blood, storage conditions and duration, volumes, training, 
international standards, calibration materials, and analytical systems—automated 
hematology analyzers, point-of-care analyzers, cyanmethemoglobin measurement by 
spectrophotometry, filter paper-based methods, clinical evaluation (e.g., examination for 
conjunctival or palmar pallor), or noninvasive measures (i.e., pulse oximetry)—in guidelines 
should be addressed.
Despite the limitations of available data, the complex questions raised, and the clear need for 
information, outcomes of this technical meeting contribute to the Member States’ efforts to 
strengthen their health systems. This supplement provides a summary of technical 
considerations that can be useful in developing policies around diagnosis of anemia and its 
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causes to inform implementation of nutrition-specific and nutrition-sensitive programs. It 
will ultimately contribute to WHO’s ongoing normative work in this field.
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coordinators preliminary supervision of both technical conformity to the publishing 
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authors alone are responsible for the views expressed in this paper; they do not 
necessarily represent the views, decisions, or policies of the WHO or the Centers for 
Disease Control and Prevention. The findings and conclusions in this report are those of 
the authors and are not attributable to or represent the official position of the World 
Health Organization, the Centers for Disease Control and Prevention, the sponsors, 
publisher, or editorial staff of Annals of the New York Academy of Sciences.
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11
.M
od
el
in
g 
of
 c
ut
of
f p
oi
nt
s f
or
 
di
ag
no
sin
g 
an
em
ia
B
lo
od
 b
an
ks
, b
io
ba
nk
s, 
an
d 
ot
he
r a
ca
de
m
ic
, c
lin
ic
al
, o
r e
du
ca
tio
na
l d
at
ab
as
es
 in
 d
iff
er
en
t c
ou
nt
rie
s w
ith
 “
he
al
th
y”
 in
di
v
id
ua
ls 
an
d 
th
e 
fe
as
ib
ili
ty
 fo
r d
ev
el
op
in
g 
cu
to
ffp
oi
nt
s t
o 
di
ag
no
se
 a
ne
m
ia
.
Pr
op
os
al
s b
as
ed
 o
n 
ev
id
en
ce
 a
nd
 m
at
he
m
at
ic
al
 m
od
el
s o
n 
cu
to
ff 
po
in
ts 
fo
r a
ne
m
ia
 fo
r a
ll 
ge
nd
er
,
 
ag
e,
 p
hy
sio
lo
gi
ca
l a
nd
 p
at
ho
ph
ys
io
lo
gi
ca
l c
on
di
tio
ns
, c
ul
tu
ra
l, 
ge
og
ra
ph
ic
al
, o
r t
ra
di
tio
ns
 g
ro
up
s w
he
re
 th
er
e 
is 
no
t e
no
ug
h 
ev
id
en
ce
 to
 p
ro
po
se
 a
 c
ut
of
fp
oi
nt
.
12
.C
ou
nt
ry
 ex
pe
rie
nc
es
 a
nd
 
ca
se
 s
tu
di
es
To
 d
es
cr
ib
e 
th
e 
co
un
try
’s
 ex
pe
rie
nc
e 
an
d 
hi
sto
ry
 w
ith
 a
ne
m
ia
 d
ia
gn
os
es
 b
as
ed
 o
n 
he
m
og
lo
bi
n 
de
te
rm
in
at
io
n 
an
d 
th
e 
va
lid
at
io
n 
of
 o
th
er
 m
ar
ke
rs
 a
t p
op
ul
at
io
n 
le
v
el
.
D
es
cr
ip
tio
n 
of
 su
cc
es
sf
ul
 p
ro
gr
am
s o
n 
ch
an
gi
ng
 p
re
v
al
en
ce
 o
f a
ne
m
ia
 a
nd
/o
r t
ho
se
 w
ith
ou
t c
ha
ng
es
 in
 p
re
v
al
en
ce
 o
f a
ne
m
ia
, b
u
t i
m
pr
ov
ed
 h
em
og
lo
bi
n 
co
n
ce
n
tr
at
io
ns
.
N
OT
E:
 T
o
pi
cs
 w
er
e 
se
le
ct
ed
 fr
om
 th
e 
six
 c
at
eg
or
ie
s i
de
nt
ifi
ed
 b
y 
th
e 
pr
io
rit
iz
at
io
n 
ex
er
ci
se
.
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